2025 Germany Anti-Infective Vaccines Market Revenue Opportunities Report
Description
The 2025 Germany Anti-Infective Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-infective vaccines market in Germany are Bayer, BioNTech, Pfizer, and GSK. Bayer, headquartered in Leverkusen, is a global pharmaceutical leader with a broad portfolio including anti-infective and vaccine development, contributing significantly to Germany's pharma export strength. BioNTech, based in Planegg, is renowned for its mRNA vaccine platform and co-developed the COVID-19 vaccine with Pfizer, expanding its pipeline to include vaccines for influenza, shingles, HIV, and more. Pfizer itself, a major global vaccine developer, leads with vaccines like Prevnar 20 and has a strong presence in Germany through partnerships with BioNTech and its own local infrastructure. GSK operates multiple sites in Germany, specializing in influenza and hepatitis vaccines, holding a substantial market share in anti-infective vaccines.
These companies blend innovation with large-scale manufacturing and distribution in Germany, reflecting the country’s rich talent pool and focus on R&D. Bayer combines extensive therapeutic areas including cardiovascular and oncology with its vaccine efforts. BioNTech’s emerging mRNA candidates target various infectious diseases with ongoing clinical trials. Pfizer maintains dominance in pneumococcal vaccines and expands globally through robust networks. GSK focuses on respiratory and pandemic vaccines, maintaining about 20-25% market share with products like Arexvy and Shingrix. Together, they shape Germany’s role as a pharmaceutical hub and key player in the global anti-infective vaccine market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-infective vaccines market in Germany are Bayer, BioNTech, Pfizer, and GSK. Bayer, headquartered in Leverkusen, is a global pharmaceutical leader with a broad portfolio including anti-infective and vaccine development, contributing significantly to Germany's pharma export strength. BioNTech, based in Planegg, is renowned for its mRNA vaccine platform and co-developed the COVID-19 vaccine with Pfizer, expanding its pipeline to include vaccines for influenza, shingles, HIV, and more. Pfizer itself, a major global vaccine developer, leads with vaccines like Prevnar 20 and has a strong presence in Germany through partnerships with BioNTech and its own local infrastructure. GSK operates multiple sites in Germany, specializing in influenza and hepatitis vaccines, holding a substantial market share in anti-infective vaccines.
These companies blend innovation with large-scale manufacturing and distribution in Germany, reflecting the country’s rich talent pool and focus on R&D. Bayer combines extensive therapeutic areas including cardiovascular and oncology with its vaccine efforts. BioNTech’s emerging mRNA candidates target various infectious diseases with ongoing clinical trials. Pfizer maintains dominance in pneumococcal vaccines and expands globally through robust networks. GSK focuses on respiratory and pandemic vaccines, maintaining about 20-25% market share with products like Arexvy and Shingrix. Together, they shape Germany’s role as a pharmaceutical hub and key player in the global anti-infective vaccine market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
